I guess I'll stick this in here- for Rick- since he seems to know everyone dating back to HMS Beagle (talk has it he knew Pasteur' too). Anyway, he's getting kinda testy over onT/FIF. pax et bonum, mch
DOW JONES
PUBLICATIONS
LIBRARY SEARCH
• BTRN
Michael S. Perry Joins BioTransplant's Board of Directors
February 18, 1999 8:29 AM EST
CHARLESTOWN, Mass., Feb. 18 /PRNewswire/ -- BioTransplant Incorporated (Nasdaq: BTRN) announced today the appointment to its Board of Directors of Michael S. Perry, D.V.M., Ph.D., President and CEO of Novartis subsidiaries Genetic Therapy, Inc. and SyStemix, Inc., which are responsible for Novartis' pioneering work in cell and gene therapy. Dr. Perry has several years of senior management experience in clinical development and regulatory affairs at Novartis Pharmaceuticals Corp.
"Dr. Perry brings to BioTransplant a wealth of perspective and expertise in clinical and regulatory strategies, and he will be a valuable asset as BioTransplant advances its XenoMune(TM) System and other immune re-education and transplant products," said Elliot Lebowitz, Ph.D., President and Chief Executive Officer of BioTransplant. "With Dr. Daniel Hauser's recent retirement from Novartis, Dr. Perry will be the Novartis representative on our board while Dr. Hauser will continue to serve on the board as a valuable independent member."
Dr. Perry has held multiple senior management positions in the pharmaceutical industry, including: Vice President of Drug Regulatory Affairs, North America at Novartis; Vice President of Drug Registration and Regulatory Affairs, USA at Sandoz Pharmaceuticals Corporation (now Novartis); and Vice President of Human Pharmaceutical Regulatory Affairs at Syntex Corporation. He is a Board-certified Doctor of veterinary medicine and surgery, and holds a Ph.D. in pharmacology and a B.Sc. in physics from the University of Guelph, Ontario, Canada.
"Novartis became a leader in transplantation by pioneering immunosuppression and recognizes that novel solutions may be required to expand the supply of organs available for transplantation," said Dr. Perry. "Novartis is fully committed to those patients in need of an organ transplant, and BioTransplant's proprietary new technologies offer the potential to be a valuable contribution to these efforts."
BioTransplant Incorporated is developing proprietary pharmaceuticals and systems based on its unique and proprietary enabling technologies, which are designed to re-educate the body's immune system to accept foreign tissue, allowing safer and more enduring organ transplantation, and creating potentially valuable new treatments for other diseases such as blood cell cancers. The Company is initially focusing on enhancing the safety and expanding access to organ transplants. BioTransplant's transplant product candidates are intended to induce long-term functional transplantation tolerance in humans, reduce or eliminate the need for lifelong immunosuppressive therapy, and reduce the cost of treating end-stage organ disease.
This announcement may contain, in addition to historical information, certain forward looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in the Company's filings with the U.S. Securities and Exchange Commission. SOURCE BioTransplant Incorporated
© PR Newswire. All rights reserved.
Click Here
|
